Quantcast

Latest Tuberculosis treatment Stories

2012-07-24 10:10:48

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30...

2012-06-28 20:18:49

Inhibiting immune response early on could speed treatment time, prevent relapse Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could – paradoxically – shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health...

2012-06-17 23:01:34

Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine. The imm02 study was aimed to seek whether oral formulation of inactivated whole cell mycobacteria can shorten TB treatment duration. Vancouver, Canada (PRWEB) June 17, 2012 The phase II, placebo-controlled trial, conducted by experts in the field of TB immunotherapy, was set to evaluate the efficacy of tableted, heat-killed Mycobacterium vaccae in...

2012-06-08 05:20:54

(Ivanhoe Newswire) -- In 2010 the World Health Organization (WHO) estimated there were 290,000 cases of multi-drug resistant tuberculosis globally. Now a new medication attempts to slash those numbers. Delamanid, a nitro-dihydro-imidazooxazole derivative, is a new medication that inhibits mycolic acid synthesis (long fatty acids found in the cell walls of the mycolata taxon) and has shown potent in vitro (half living-in a Petri dish) and in vivo (living in the body) activity against drug...

2012-05-17 23:12:16

A joint Innovation Summit seeks to find solutions for identified barriers to treating tuberculosis. Boston, MA (PRWEB) May 17, 2012 Leading global public health experts and NGO and business leaders will convene for two days in Lexington, Massachusetts to identify innovative solutions for improving the treatment of multi-drug resistant tuberculosis (MDR-TB), which kills more than 150,000 people each year. The goal of the Innovation Summit, jointly organized by The Lilly MDR-TB Partnership...

2012-04-02 09:12:31

Today, the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC) publish their jointly developed European Union Standards for Tuberculosis Care (ESTC). The 21 patient-centered standards aim to guide clinicians and public health workers to ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) in Europe — with nearly 74,000 reported TB cases in the EU/EEA in 2010 clearly showing that TB remains a public health challenge...

2012-03-27 08:34:42

A two-drug combination is one of the most promising advances in decades for the treatment of tuberculosis (TB) – a disease that kills 2 million people annually – a scientist reported today at the 243 National Meeting & Exposition of the American Chemical Society (ACS). The treatment, which combines two medications already approved by the U.S. Food and Drug Administration (FDA), delivers a knockout punch to forms of TB that shrug off other antibiotics. ACS, the world's...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related